Statements (34)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
LSD
amphetamine Hallucinogen |
| gptkbp:actsOn |
5-HT2A receptor agonist
|
| gptkbp:CASNumber |
1354631-77-6
|
| gptkbp:chemicalFormula |
C19H25N2O
|
| gptkbp:designer_drug |
yes
|
| gptkbp:discoveredBy |
2010
|
| gptkbp:first_identified_by |
forensic laboratories
|
| https://www.w3.org/2000/01/rdf-schema#label |
25P-NBOMe
|
| gptkbp:IUPACName |
2-(4-propyl-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine
|
| gptkbp:legalStatus |
illegal in the United Kingdom
Schedule I in Canada controlled in China illegal in Sweden |
| gptkbp:marketedAs |
research chemical
|
| gptkbp:molecularWeight |
297.42 g/mol
|
| gptkbp:relatedTo |
gptkb:25I-NBOMe
gptkb:2C-P |
| gptkbp:routeOfAdministration |
oral
sublingual buccal |
| gptkbp:sideEffect |
nausea
anxiety hypertension seizures tachycardia hallucinations death (in overdose) vasoconstriction |
| gptkbp:structural_analog_of |
gptkb:2C-P
|
| gptkbp:usedFor |
recreational purposes
|
| gptkbp:bfsParent |
gptkb:NBOMe_series
|
| gptkbp:bfsLayer |
7
|